Ipilimumab in Non-Small Cell Lung Cancer

Drug class Target Agent Diseases Line of Therapy Status Source
CTLA-4 inhibitors, Immunotherapy, Monoclonal antibody CTLA-4 ipilimumab (Yervoy) non-small cell lung cancer metastatic Trials complete with results Lynch et al. 2012

The efficacy and safety of anti-CTLA-4 molecules for the treatment of patients with non-small cell lung cancer (NSCLC) is currently under investigation. Ipilimumab has shown promise in treating patients with metastatic NSCLC in one phase II trial (Lynch et al. 2012). This has led to ongoing phase III trials of ipilimumab in the treatment of patients with metastatic NSCLC (NCT01285609; Langer 2014).

Reference Study Type / Phase Line of Treatment Treatment Agent Mutation Status # Patients in Study Response Rate PFS (months) OS (months)
Lynch et al. 2012 Phase II 1st concurrent ipilimumab + carboplatin + paclitaxel   70 21% 4.1 9.7
phased ipilimumab + carboplatin + paclitaxel   68 32% 5.1 12.2
carboplatin + paclitaxel   66 14% 4.2 8.3
NOTE: OS = overall survival; PFS = progression-free survival

Contributors: Wade T. Iams, M.D., Douglas Johnson, M.D., Christine M. Lovly, M.D., Ph.D.

Suggested Citation: Iams, W.T., D. Johnson, C. Lovly. 2015. Immunotherapy in Cancer. My Cancer Genome http://www.padiracinnovation.org/content/molecular-medicine/c2654-non-small-cell-lung-cancer/ (Updated February 10).


Last Updated: June 24, 2015

Disclaimer: The information presented at padiracinnovation.org is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.